JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology ...
The average one-year price target for Dyadic International (NasdaqCM:DYAI) has been revised to $7.14 / share. This is an ...
JUPITER, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...
Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against ...
JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the ...
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal ...
Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical ...
Dyadic International said today it will sell its industrial technology business to DuPont’s Industrial Biosciences business for $75 million cash, in a deal that will reposition the seller exclusively ...
Aiming for the courtroom equivalent of a pin, former collegiate wrestler Mark Emalfarb alleged blue-chip law firms robbed his biotech company of $185 million in vanished market capitalization and $700 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback